Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells

S. Sebastian, Amalia Azzariti, R. Accardi, D. Conti, B. Pilato, R. Lacalamita, L. Porcelli, G. M. Simone, S. Tommasi, M. Tommasino, A. Paradiso

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recently improved understanding of the pathogenesis of human head and neck squamous cell carcinoma (HNSCC) has led to the development of new, molecular-based therapeutic strategies, one of the more promising is the utilisation of tyrosine kinase (TK) inhibitors, targeting epidermal growth factor receptor (EGFR). In this study, we tested for gefitinib effectiveness in a broad panel of 12 newly established HNSCC cell lines, investigating its ability to reduce cell growth, to induce apoptosis and to modulate cell cycle and various EGFR pathway-related targets. Gefitinib IC50 values ranged between 0.064 and 33 μM, its capability to induce apoptosis and cell accumulation in G0/G1 phase was cell line-specific, and the main EGFR-related pathway involved in gefitinib activity was PI3K/Akt/mTor. We characterised our in vitro panel extensively, with the aim to identify predictive factors for gefitinib effectiveness; all cell lines were free of human papillomavirus infection, two were positive for Fhit expression, four expressed wild-type p53, and all of them variously expressed the other two p53 family members, p63 and p73. The comparison between the targets analysed and gefitinib effectiveness evidenced the absence of a clear relationship, excluding them as predictive factors for gefitinib efficacy. Our results confirmed the in vitro efficacy of an anti-EGFR approach, but other targets than those analysed here should be characterised in order to identify valid predictive factors for gefitinib utilisation.

Original languageEnglish
Pages (from-to)809-817
Number of pages9
JournalInternational Journal of Molecular Medicine
Volume21
Issue number6
Publication statusPublished - Jun 2008

Fingerprint

Epidermal Growth Factor Receptor
Cell Line
Apoptosis
Cell Cycle Resting Phase
Aptitude
Papillomavirus Infections
G1 Phase
gefitinib
Carcinoma, squamous cell of head and neck
Phosphatidylinositol 3-Kinases
Protein-Tyrosine Kinases
Inhibitory Concentration 50
Cell Cycle
Growth
In Vitro Techniques
Therapeutics

Keywords

  • Gefitinib sensitivity
  • Head and neck squamous carcinoma cell lines
  • Molecular characterization

ASJC Scopus subject areas

  • Genetics

Cite this

Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. / Sebastian, S.; Azzariti, Amalia; Accardi, R.; Conti, D.; Pilato, B.; Lacalamita, R.; Porcelli, L.; Simone, G. M.; Tommasi, S.; Tommasino, M.; Paradiso, A.

In: International Journal of Molecular Medicine, Vol. 21, No. 6, 06.2008, p. 809-817.

Research output: Contribution to journalArticle

Sebastian, S. ; Azzariti, Amalia ; Accardi, R. ; Conti, D. ; Pilato, B. ; Lacalamita, R. ; Porcelli, L. ; Simone, G. M. ; Tommasi, S. ; Tommasino, M. ; Paradiso, A. / Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. In: International Journal of Molecular Medicine. 2008 ; Vol. 21, No. 6. pp. 809-817.
@article{3446f5b4726c4975ad4b115bd3b670cf,
title = "Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells",
abstract = "Recently improved understanding of the pathogenesis of human head and neck squamous cell carcinoma (HNSCC) has led to the development of new, molecular-based therapeutic strategies, one of the more promising is the utilisation of tyrosine kinase (TK) inhibitors, targeting epidermal growth factor receptor (EGFR). In this study, we tested for gefitinib effectiveness in a broad panel of 12 newly established HNSCC cell lines, investigating its ability to reduce cell growth, to induce apoptosis and to modulate cell cycle and various EGFR pathway-related targets. Gefitinib IC50 values ranged between 0.064 and 33 μM, its capability to induce apoptosis and cell accumulation in G0/G1 phase was cell line-specific, and the main EGFR-related pathway involved in gefitinib activity was PI3K/Akt/mTor. We characterised our in vitro panel extensively, with the aim to identify predictive factors for gefitinib effectiveness; all cell lines were free of human papillomavirus infection, two were positive for Fhit expression, four expressed wild-type p53, and all of them variously expressed the other two p53 family members, p63 and p73. The comparison between the targets analysed and gefitinib effectiveness evidenced the absence of a clear relationship, excluding them as predictive factors for gefitinib efficacy. Our results confirmed the in vitro efficacy of an anti-EGFR approach, but other targets than those analysed here should be characterised in order to identify valid predictive factors for gefitinib utilisation.",
keywords = "Gefitinib sensitivity, Head and neck squamous carcinoma cell lines, Molecular characterization",
author = "S. Sebastian and Amalia Azzariti and R. Accardi and D. Conti and B. Pilato and R. Lacalamita and L. Porcelli and Simone, {G. M.} and S. Tommasi and M. Tommasino and A. Paradiso",
year = "2008",
month = "6",
language = "English",
volume = "21",
pages = "809--817",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells

AU - Sebastian, S.

AU - Azzariti, Amalia

AU - Accardi, R.

AU - Conti, D.

AU - Pilato, B.

AU - Lacalamita, R.

AU - Porcelli, L.

AU - Simone, G. M.

AU - Tommasi, S.

AU - Tommasino, M.

AU - Paradiso, A.

PY - 2008/6

Y1 - 2008/6

N2 - Recently improved understanding of the pathogenesis of human head and neck squamous cell carcinoma (HNSCC) has led to the development of new, molecular-based therapeutic strategies, one of the more promising is the utilisation of tyrosine kinase (TK) inhibitors, targeting epidermal growth factor receptor (EGFR). In this study, we tested for gefitinib effectiveness in a broad panel of 12 newly established HNSCC cell lines, investigating its ability to reduce cell growth, to induce apoptosis and to modulate cell cycle and various EGFR pathway-related targets. Gefitinib IC50 values ranged between 0.064 and 33 μM, its capability to induce apoptosis and cell accumulation in G0/G1 phase was cell line-specific, and the main EGFR-related pathway involved in gefitinib activity was PI3K/Akt/mTor. We characterised our in vitro panel extensively, with the aim to identify predictive factors for gefitinib effectiveness; all cell lines were free of human papillomavirus infection, two were positive for Fhit expression, four expressed wild-type p53, and all of them variously expressed the other two p53 family members, p63 and p73. The comparison between the targets analysed and gefitinib effectiveness evidenced the absence of a clear relationship, excluding them as predictive factors for gefitinib efficacy. Our results confirmed the in vitro efficacy of an anti-EGFR approach, but other targets than those analysed here should be characterised in order to identify valid predictive factors for gefitinib utilisation.

AB - Recently improved understanding of the pathogenesis of human head and neck squamous cell carcinoma (HNSCC) has led to the development of new, molecular-based therapeutic strategies, one of the more promising is the utilisation of tyrosine kinase (TK) inhibitors, targeting epidermal growth factor receptor (EGFR). In this study, we tested for gefitinib effectiveness in a broad panel of 12 newly established HNSCC cell lines, investigating its ability to reduce cell growth, to induce apoptosis and to modulate cell cycle and various EGFR pathway-related targets. Gefitinib IC50 values ranged between 0.064 and 33 μM, its capability to induce apoptosis and cell accumulation in G0/G1 phase was cell line-specific, and the main EGFR-related pathway involved in gefitinib activity was PI3K/Akt/mTor. We characterised our in vitro panel extensively, with the aim to identify predictive factors for gefitinib effectiveness; all cell lines were free of human papillomavirus infection, two were positive for Fhit expression, four expressed wild-type p53, and all of them variously expressed the other two p53 family members, p63 and p73. The comparison between the targets analysed and gefitinib effectiveness evidenced the absence of a clear relationship, excluding them as predictive factors for gefitinib efficacy. Our results confirmed the in vitro efficacy of an anti-EGFR approach, but other targets than those analysed here should be characterised in order to identify valid predictive factors for gefitinib utilisation.

KW - Gefitinib sensitivity

KW - Head and neck squamous carcinoma cell lines

KW - Molecular characterization

UR - http://www.scopus.com/inward/record.url?scp=47649117616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649117616&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 809

EP - 817

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 6

ER -